1. Home
  2. NXJ vs LRMR Comparison

NXJ vs LRMR Comparison

Compare NXJ & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen New Jersey Qualified Municipal Fund

NXJ

Nuveen New Jersey Qualified Municipal Fund

HOLD

Current Price

$12.63

Market Cap

503.5M

Sector

Finance

ML Signal

HOLD

Logo Larimar Therapeutics Inc.

LRMR

Larimar Therapeutics Inc.

HOLD

Current Price

$3.46

Market Cap

316.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXJ
LRMR
Founded
1999
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
503.5M
316.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NXJ
LRMR
Price
$12.63
$3.46
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$16.71
AVG Volume (30 Days)
74.9K
1.1M
Earning Date
01-01-0001
11-05-2025
Dividend Yield
3.27%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.06
$1.61
52 Week High
$12.24
$5.37

Technical Indicators

Market Signals
Indicator
NXJ
LRMR
Relative Strength Index (RSI) 45.01 41.66
Support Level $12.59 $3.34
Resistance Level $12.69 $4.01
Average True Range (ATR) 0.11 0.25
MACD -0.01 -0.02
Stochastic Oscillator 57.89 14.81

Price Performance

Historical Comparison
NXJ
LRMR

About NXJ Nuveen New Jersey Qualified Municipal Fund

Nuveen New Jersey Quality Municipal Income Fund is a closed-end investment management company. Its objective is to provide current income exempt from regular federal and New Jersey income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. The company invests a majority of its managed assets in securities rated, at the time of investment, investment grade or, if the bonds are unrated, are judged by the manager to be of comparable quality.

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Share on Social Networks: